Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
08:00am, Monday, 27'th Oct 2025
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®
08:00am, Thursday, 23'rd Oct 2025
-- Findings Presented at AMCP Nexus 2025 Annual Meeting -- BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovativ
Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Tuesday, 21'st Oct 2025
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
08:30am, Tuesday, 21'st Oct 2025
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
-- Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in i
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 03'rd Oct 2025
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Sep 2025
BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pat
Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript
02:42am, Wednesday, 06'th Aug 2025
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Brendan P. Teehan - Chief Commercial Officer Frank D.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings
09:01pm, Tuesday, 05'th Aug 2025
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Pacira BioSciences Reports Second Quarter 2025 Financial Results
04:00pm, Tuesday, 05'th Aug 2025
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth --
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
08:00am, Thursday, 24'th Jul 2025
BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
SAN DIEGO , July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purch
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 03'rd Jul 2025
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
12:11pm, Wednesday, 18'th Jun 2025
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ
